BERLIN — Akeso and Summit Therapeutics’ PD-1xVEGF bispecific ivonescimab cut the risk of disease progression or death by 40% compared to the PD-1 blocker Tevimbra, when both drugs were given on top of chemotherapy as a ...
↧